EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors

Junjun Liu, Jianwei Zhu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112609 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Junjun Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 2002…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms, T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology, National Major Science and Technology Projects of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate tumor cells. The therapeutic potential of TCBs has been well recognized, particularly with the approval of multiple TCBs in recent years for the treatment of hematologic malignancies as well as some solid tumors. However, TCBs encounter multiple challenges in treating solid tumors, such as on-target off-tumor toxicity, cytokine release syndrome (CRS), and T cell dysfunction within the immunosuppressive tumor microenvironment, all of which may impact their therapeutic efficacy. In this review, we summarize clinical data on TCBs for solid tumor treatment, highlight the challenges faced, and discuss potential solutions based on emerging strategies from current clinical and preclinical research. These solutions include TCB structural optimization, target selection, and combination strategies. This comprehensive analysis aims to guide the development of TCBs from design to clinical application, addressing the evolving landscape of cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificNeoplasmsT-LymphocytesImmunotherapyTumor MicroenvironmentHumansAnimalsAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Cytokine release syndromeImmunotherapeuticOn-target off-tumor toxicitySolid tumorT-cell-engaging bispecific antibody

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China; Jecho Laboratories, Inc., Frederick, MD 21704, USA. Electro…

Förderung

  • National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology
  • National Major Science and Technology Projects of China
  • National Natural Science Foundation of China

Zitieren

APA

Liu, J., & Zhu, J. (2024). Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112609

Vancouver

Liu J, Zhu J. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112609

BibTeX
@article{Liu2024,
  author = {Liu, Junjun and Zhu, Jianwei},
  title = {Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112609}
}
Kostenlos starten →